| 1 |
35164144 | Conjugation of Palbociclib with MHI-148 Has an Increased Cytotoxic Effect for Breast Cancer Cells and an Altered Mechanism of Action. | 2022 Jan 27 |
2 |
| 2 |
35241469 | Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. | 2022 Mar 3 |
1 |
| 3 |
35350768 | The Resistance of Cancer Cells to Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, is Mediated by the ABCB1 Transporter. | 2022 |
1 |
| 4 |
33356791 | Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. | 2021 Jan |
1 |
| 5 |
33407601 | Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy. | 2021 Jan 6 |
1 |
| 6 |
33676547 | Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. | 2021 Mar 6 |
1 |
| 7 |
33835229 | Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. | 2021 Jul |
1 |
| 8 |
34244855 | The mechanisms involved in the resistance of estrogen receptor-positive breast cancer cells to palbociclib are multiple and change over time. | 2021 Nov |
2 |
| 9 |
34388698 | Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2. | 2021 Oct |
1 |
| 10 |
34657057 | [Successful Treatment of Estrogen Receptor Positive, HER2 Negative Breast Cancer with Life-Threatening Multiple Bone Metastases Using the Combination of Fulvestrant and Palbociclib-A Case Report]. | 2021 Oct |
2 |
| 11 |
31649043 | FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer. | 2020 Mar 15 |
1 |
| 12 |
32130619 | G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. | 2020 Apr |
3 |
| 13 |
32164162 | Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib. | 2020 Mar 10 |
1 |
| 14 |
32453591 | Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. | 2020 Jul 9 |
1 |
| 15 |
32723837 | Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. | 2020 Nov 15 |
1 |
| 16 |
32938620 | Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. | 2020 Nov 15 |
1 |
| 17 |
30523750 | Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial. | 2019 Jan 20 |
2 |
| 18 |
30745839 | Combined Androgen receptor blockade overcomes the resistance of breast cancer cells to palbociclib. | 2019 |
1 |
| 19 |
30772267 | Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex. | 2019 May |
1 |
| 20 |
30867218 | Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. | 2019 Jul 1 |
1 |
| 21 |
31217344 | Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2- Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial. | 2019 Dec |
2 |
| 22 |
31330844 | Palbociclib Promotes Dephosphorylation of NPM/B23 at Threonine 199 and Inhibits Endometrial Cancer Cell Growth. | 2019 Jul 20 |
1 |
| 23 |
31371343 | FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. | 2019 Nov 1 |
1 |
| 24 |
31640597 | Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report. | 2019 Oct 22 |
1 |
| 25 |
29337187 | Metabolomics Reveals that Dietary Xenoestrogens Alter Cellular Metabolism Induced by Palbociclib/Letrozole Combination Cancer Therapy. | 2018 Mar 15 |
2 |
| 26 |
29893790 | Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. | 2018 Aug 1 |
1 |
| 27 |
30069766 | Palbociclib-The First of a New Class of Cell Cycle Inhibitors. | 2018 |
1 |
| 28 |
28856074 | Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient. | 2017 Jun 29 |
2 |
| 29 |
28978004 | Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. | 2017 Sep 15 |
1 |
| 30 |
29261702 | Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells. | 2017 |
2 |
| 31 |
26857361 | Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. | 2016 Feb 9 |
1 |
| 32 |
27009458 | Hyperuricemia in 2 Patients Receiving Palbociclib for Breast Cancer. | 2016 Jan |
3 |
| 33 |
27274308 | Profile of palbociclib in the treatment of metastatic breast cancer. | 2016 |
1 |
| 34 |
27785059 | Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer. | 2016 |
1 |
| 35 |
26324739 | FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer. | 2015 Nov 1 |
1 |